Trial Profile
A phase II study of cetuximab (C225)/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Jun 2009 Trial phase changed from IV to II as reported by ClinicalTrials.gov.
- 30 Jun 2009 Trial phase changed from IV to II as reported by ClinicalTrials.gov.
- 08 Dec 2008 Status changed from active, no longer recruiting to completed.